Data / Form D filings / Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc.: Form D filings
Werewolf Therapeutics, Inc., a pharmaceuticals company in Cambridge, MA, filed 3 Form D notices with the SEC between 2019 and 2021. The latest, on January 7, 2021, reports $72.1 million sold of a $72.1 million offering to 19 investors.
Find out what Werewolf Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1030 MASSACHUSETTS AVENUE, SUITE 210, Cambridge, MA, 02138
- Phone
- (617) 952-0555
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2017
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1785530
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 7, 2021 | New notice | $72,069,999 | $72,069,999 | $0 | 19 | Dec 23, 2020 | sec.gov |
| Aug 13, 2020 | Amendment | $56,172,597 | $56,172,597 | $0 | 10 | Aug 2, 2019 | sec.gov |
| Aug 15, 2019 | New notice | $57,672,595 | $31,572,600 | $26,099,995 | 9 | Aug 2, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Luke Evnin | Director | |
| Briggs Morrison | Director | |
| Daniel Hicklin | Executive Officer, Director | |
| Sakae Asanuma | Director | |
| Alon Lazarus | Director | |
| Elise Wang | Director | |
| David Cordo | Executive Officer | |
| Derek DiRocco | Director |
Other pharmaceuticals companies in Massachusetts that filed recently
- BridgeHealth Pharmaceuticals, Inc. $3.5 million · Nov 5, 2026
- Land Therapeutics Inc. $17.5 million · Oct 21, 2026
- Crosslink Therapeutics Inc. $5.5 million · Oct 20, 2026
- Sentonix, Inc. $12.7 million · Aug 20, 2026
Every Form D from the week of Jan 4, 2021 · All recent filings in Massachusetts · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Werewolf Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.